PRC
KYNB

Pearl River Capital’s Kyntra Bio KYNB Stock Holding History

Pearl River Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-551
Closed -$479K – 464
2021
Q1 		$479K Buy
+551
New +$587K 0.15% 203
2019
Q2 		– Sell
-2
Closed -$2K – 350
2019
Q1 		$2K Sell
2
-6
-75% -$8.14K 0.01% 338
2018
Q4 		$10K Buy
+8
New +$8.99K 0.05% 542

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pearl River Capital's KYNB Position: Q2 2021 in Review

Pearl River Capital sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 551 shares — an estimated $479K sold.

Pearl River Capital first reported a position in KYNB in Q4 2018 and held it in 3 quarters. The position peaked at $479K in Q1 2021. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Pearl River Capital reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Pearl River Capital sold 551 Kyntra Bio shares in Q2 2021, an estimated $479K.
  • Pearl River Capital first reported a position in Kyntra Bio in Q4 2018 and held it in 3 quarters.
  • Pearl River Capital's Kyntra Bio position peaked at $479K in Q1 2021.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Pearl River Capital's 13F filing for Q2 2021, filed 13 Aug 2021.